XRCC1抗体;XRCC1 Antibody—艾普蒂

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: 293T cells, Primary antibody: P00029(UPK3B Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P00029(UPK3B Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P00029(UPK3B Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The XRCC1 (X-ray repair cross-complementing protein 1) antibody is a crucial tool for studying DNA repair mechanisms, particularly base excision repair (BER) and single-strand break repair (SSBR). XRCC1 is a scaffold protein that lacks enzymatic activity but coordinates key repair components, including DNA ligase IIIα, PARP1. and polynucleotide kinase, to maintain genomic stability. Antibodies targeting XRCC1 are widely used in research to detect its expression, localization, and interaction partners in various biological contexts. They are employed in techniques such as Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF) to investigate XRCC1’s role in cellular responses to DNA damage induced by radiation, oxidative stress, or chemotherapeutic agents.

XRCC1 antibodies are typically raised in rabbits or mice using immunogenic peptides or recombinant protein fragments, with monoclonal and polyclonal variants available. These antibodies help elucidate XRCC1’s involvement in diseases linked to defective DNA repair, including cancer, neurodegenerative disorders, and aging-related pathologies. For example, reduced XRCC1 expression or polymorphisms in its gene have been associated with increased cancer susceptibility. Researchers also use these antibodies to explore XRCC1’s potential as a biomarker for predicting therapeutic responses or prognosis in patients undergoing DNA-damaging treatments. Validation via knockout cell lines or siRNA knockdown is critical to ensure antibody specificity due to XRCC1’s complex protein interactions.